The best Drug Discovery newsletters

A physician-scientist's newsletter of in-depth analyses of human genetics papers, drug programmes and rare disease stories, plus roundups of notable discoveries. Issues dig into specific findings with clear explanation of the underlying science and why it matters.

Long-form essays on biology, drug discovery and machine learning, currently a three-part series on whether organoids have delivered on their promise. The author, who works on health data philanthropy, offers skeptical, opinionated analysis of the scientific literature with occasional life and job updates.

This blog covers Open Targets Platform release announcements, with detailed notes on new genomics datasets and pipeline improvements, alongside stories about the research behind them. Readers get first-hand updates on data for drug target identification and prioritisation.

Long-form essays on the frontier of biology, covering research institutions, AI-driven drug discovery, and biotech founders. Readers get narrative-driven analysis that connects data, companies, and ideas from the life sciences and biotech investing.

Creode is a personal essay newsletter by a therapeutics researcher covering life sciences, machine learning, and drug discovery. Issues argue for specific strategic priorities, such as using AI and genomics to expand drug targets and reverse declining R&D productivity, and explain the reasoning with historical and conceptual framing.

A weekly newsletter tracking AI and computational drug discovery, covering deals, startups, funding rounds and research papers in biopharma. Each issue pairs a main analytical essay with a roundup of recent industry news.

BioPharmaBrief covers biotech and pharma developments, including drug discovery, clinical trial outcomes, regulatory decisions and financing. Its issues mix explanatory features, company profiles and analysis of health technology such as wearables.

Kaleidoscope, a biotech R&D company, publishes essays on the economics and operations of drug development, covering talent motivation, the shift of early trials to China, and inefficiencies in lab operations. Readers get founder-level perspective on the business and strategy of biopharma, with a focus on where AI can practically help.

MoleculeInsight is a blog-style newsletter of essays on modern drug discovery, explaining concepts such as plasma protein binding, molecular interactions, hit discovery and ADME. It also covers the newsletter's educational product MedChemify and wider links between AI, 3D modelling and molecular science.

A daily brief covering AI agents in biomedical and drug discovery, pairing short news items with 'why it matters' commentary on each. The sample issues cover OpenAI's acquisition of a drug-development agent startup, lab-designed binders and benchmark studies of agent reliability.

A corporate blog from Genetic Leap, a company using AI and computational platforms for genetically-defined drug target selection and RNA-targeted therapeutics. Posts cover company news, conference appearances and technical perspectives on experimental validation of AI-driven predictions.

A weekly automated digest that compiles and briefly summarises recent peer-reviewed papers at the intersection of machine learning, computational biology and drug discovery. Readers get a quick scan of notable protein design, single-cell and genomics studies, each with a one-line description and publication details.

Corporate blog from Data4Cure, a biomedical AI company, announcing conference posters and describing its platform components such as the CURIE knowledge graph and AI layer. Readers get product and research announcements with marketing-heavy descriptions of the company's technology.